Identifying relevant animal challenge models adds to the complexity of human vaccine development. Murine challenge models have been the most utilized animal model for Chlamydia trachomatis vaccine development. The question arises as to whether the C. trachomatis or C. muridarum pre-clinical model is optimal. We compared C. muridarum and C. trachomatis intravaginal challenge models in a combined total of seventy-five studies evaluating potential vaccine candidates. In 100% (42/42) of C. muridarum studies, mice immunized with Chlamydia elementary bodies (EB) demonstrated a significant reduction in urogenital bacterial shedding as measured by qPCR (p < 0.05) compared to adjuvant-control-immunized mice. Significant reduction in urogenital shedding was observed for EB-immunized groups in only 82% (27/33) of C. trachomatis studies. We have evaluated proposed vaccine antigens in both models and observed immunization with Chlamydia major outer membrane protein (MOMP) vaccine formulations to be protective (p < 0.05) in both models, immunization with polymorphic membrane protein serovar D (PmpD) p73 passenger domain was protective only in the C. trachomatis model, and immunization with PmpD p82 translocator domain was not protective in either model. We also observed in both models that depletion of CD4+ T-cells in MOMP-immunized mice resulted in diminished protective immunity but animals were still able to reduce the infection level. In contrast, mice immunized with live EBs by intraperitoneal route did not require CD4+ 
Introduction
Chlamydia trachomatis is the most commonly reported disease in the United States and among the most prevalent sexually transmitted diseases. Greater than 1.6 million cases in the US and up to 131 million cases worldwide are reported annually [1] [2] [3] . Treatment is available but long-term damage to reproductive organs is common, as on average >70% of urogenital infections remain asymptomatic and are therefore largely undiagnosed [4] [5] [6] . A Chlamydia trachomatis vaccine would address a major global unmet medical need.
Several animal models have been developed to evaluate Chlamydia infections and potential vaccines. The most common is the mouse model in which two different species of Chlamydiae are used: Chlamydia muridarum, originally isolated from the lungs of reportedly normal albino Swiss mice [7] [8] , and human-derived Chlamydia trachomatis strains. Neither mouse model completely mimics C. trachomatis infection in women.
C. muridarum administered intravaginally in mice readily ascends to the upper genital tract [9] [10]. The subsequent pathology of uterine horn dilitation, hydrosalpinx, and sterility is representative of that seen in some women with post-chlamydial infection sequelae [9] [11]. C. trachomatis ascension, though, is not consistent in mice. Studies have shown ascension is dependent on serovar [12] [13], mouse strain [14] , or requires multiple daily inoculations intravaginally [15] . In contrast to C. muridarum infection, C. trachomatis urogenital infection in mice normally resolves with no pathology or obvious tissue damage [12] [15] [16] [17] similar to the majority of infections in women. Low to moderate numbers of infectious bacteria are shed in women and mice following C. trachomatis infection [16] [18] . In contrast, C. muridarum infection produces approximately 100-fold higher shedding of infectious bacteria in mice compared with C. trachomatis infection [12] [16] [19] . In women, C. trachomatis infection can become chronic and may persist for months [20] [21] [22] . In mice, chlamydial infection does not persist and usually resolves within 4 weeks, following either C. trachomatis or C. muridarum challenge [23] . Following C. muridarum infection, mice develop long lasting protective immunity [9] [16] which protects from reinfection. In contrast, reinfection can occur following C. trachomatis infection in women or mice [16] [24] .
We evaluated potential vaccine antigens in both the C. trachomatis and C. We also observed that following C. muridarum challenge, more mice in the adjuvant-control groups were infected on day 7, as determined by qPCR, compared to mice challenged with C. trachomatis serovar D. This demonstrates the C. muridarum challenge model has a broader therapeutic window for the evaluation of vaccine candidates. This finding increases confidence in results obtained with potential vaccine candidates in the C. muridarum model, and therefore in the model's ability to differentiate between candidates. We also sought to evaluate the role of CD4+ T-cells in protection from primary challenge following native MOMP (nMOMP) or live EB-immunization in both the C. muridarum and C. trachomatis mouse challenge models with C57BL/6 mice. We observed that depletion of CD4+ T-cells in nMOMP-immunized mice resulted in diminished protective immunity but the animals were still able to reduce the infection level in both challenge models. In contrast, the live EB-immunized mice did not require CD4+ T-cells to resolve urogenital infection from intravaginal challenge in either model.
Methods

Ethics Statement
All animal experiments were approved by the Merck & Co., Inc., Kenilworth, NJ, USA, Institutional Animal Care and Use Committee (IACUC). All procedures were performed in accordance with our institution's IACUC guidelines in strict accordance with the recommendations in the Guide for Care and Use of Laboratory Animals of the National Institutes of Health.
Mice were housed in large mouse containers (n = 10 mice/box) with micro isolator lids, and the rooms were maintained with controlled humidity and temperature, and 12-hour light-dark cycles. All containers had nestlets and animals were provided standard chow (Purina 5001 rodent diet) and water ad libitum.
The physical condition of the animals was monitored daily (7 days a week), and any health changes were noted.
At the end of the study, animals were euthanized using CO 2 inhalation (10% -30% CO 2 in the air mixture inhaled per minute). No animals were found to be moribund throughout the study. 
Cell Culture and Propagation of Chlamydiae
Protein Purification
C. muridarum or C. trachomatis serovar D native MOMP (nMOMP) was purified using a modified methodology from Pal et al. [25] . nMOMP was extracted from intact Chlamydia-infected HeLa cells using sonication. Initial steps used phosphate buffer with CHAPS (Calbiochem, La Jolla, CA) and 100 mM DTT (Acros Organics, Fair Lawn, NJ) and subsequently a phosphate buffer containing 
Mouse Immunization and Challenge
Female C57BL/6 mice (Taconic Farms, Hudson, NY) were used at 6 to 8 weeks Swabs were placed into a 1.5-mL tube containing 2 sterile 5 mm diameter glass beads (Corning, Corning, NY) and 300 μL of Bartels  Chlamydia isolation medium (Trinity Biotech USA, Jamestown, NY) on ice. Bacteria were eluted from the swabs and separated from cells by vortexing for 60 seconds. Eluted cells/bacteria (100 μL) were plated into a 96-well processing cartridge (Roche) containing 100 μL of PBS and stored at −80˚C until DNA extraction.
Real-Time Quantitative Polymerase Chain Reaction and Statistical Analysis
For initial studies, DNA from genital swab samples (~100 µl) was extracted us- Real-time quantitative polymerase chain reaction (RT-qPCR) was performed to confirm the presence of infection according to procedures defined in Wooters et al. [26] . Briefly, the oligonucleotide primer set was designed for detection of formed by the Log10 copy number and the day post challenge. Differences in the level of bacterial shedding between groups within each study were assessed on the AUC responses using Wilcoxon's Rank Sum Test. Differences between the C. muridarum and C. trachomatis models in the proportion of studies achieving a specified threshold were assessed using the two-sided Fisher's Exact Test. Differences between the CD4+ T-cell depleted and non-CD4+ T-cell depleted groups within the C. muridarum and C. trachomatis models in the proportion of mice resolving Chlamydial urogenital infection by day 25 were assessed using the one-sided Fisher's Exact test, given the expectation that fewer mice would resolve their infection in the CD4+ T-cell depleted group than in the non-CD4+
T-cell depleted group.
Detection of Serum Antibody Levels by ELISA
Serum was analyzed by an enzyme-linked immunosorbent assay (ELISA). Nunc where the dependent variable is the OD response and the independent variable is the log serum dilution. The resulting dilution is then back transformed to obtain the reported titer. The reported titer is the estimated dilution of serum that results in a response equivalent to the cutoff OD.
In Vivo Depletion
The anti-CD4 hybridoma GK1. When evaluating these studies, we found that in 100% (18/18) of the C. muridarum intravaginal challenge studies the nMOMP-immunized mice demonstrated EB-immunized positive control group: mice were vaginally swabbed on days ~7, 14, and 21 in the C. muridarum studies (n = 42 groups of 10 mice) or ~7, 11, 14, and 18 in the C. trachomatis studies (n = 33 groups of 10 mice). (B) 10 µg MOMP-immunized test group: mice were vaginally swabbed on days ~7, 14, and 21 in the C. muridarum studies (n = 18 groups of 10 mice) or ~7, 11, 14, and 18 in the C. trachomatis studies (n = 10 groups of 10 mice). Area under the curve (AUC) for individual mice was determined and analyzed by Wilcoxon Rank Sum Test (compared to adjuvant-control group). Resulting p-values from each study comparing the EB-immunized control group to the adjuvant-control group are shown in panels (A) and (B). Data plotted with Box and Whisker Plots (Tukey), boxes = medians with interquartile ranges (IQR), whiskers = 1.5 times the IQR distances. For the EB-immunized and MOMP-immunized groups, the difference between C. muridarum and C. trachomatis in the proportion of intravaginal challenge studies showing a significant reduction in vaginal bacterial shedding (i.e., p < 0.05) was statistically significant (p = 0.0055 and p = 0.0366, respectively). (C) Adjuvant-control group: mice were vaginally swabbed on day 7 in the C. muridarum studies (n = 42 groups of 10 mice) and in the C. trachomatis studies (n = 33 groups of 10 mice) and infection for individual mice was determined by qPCR. The percent of infected mice in the adjuvant-control group from each study is shown in panel (C). Data plotted with Box and Whisker Plots (Tukey), boxes = medians with interquartile ranges (IQR), whiskers = 1.5 times the IQR distances. The difference between C. muridarum and C. trachomatis in the proportion of intravaginal challenge studies having 100% of mice in the adjuvant-control group infected on day 7 was highly statistically significant, p < 0.0001. In initial studies we collected vaginal swab samples on both day 4 and day 7 post-challenge. We found that detectable shedding peaked on day 7 and in subsequent studies we have used day 7 as our baseline for infection level assessment. 
Evaluation of Potential Vaccine Candidates in the C. muridarum and C. trachomatis Intravaginal Challenge Models
The Chlamydia major outer membrane protein (MOMP) is a structurally and immunologically dominant protein that is surface exposed and constitutes over 60% of the total outer membrane protein mass [30] [31]. Mice vaccinated with native MOMP (nMOMP) elicit a protective immune response against both intravaginal and intrabursal challenge with C. muridarum [27] [32] [33] [34] [35] . C. trachomatis and C. muridarum purified nMOMP were evaluated as potential vaccine candidates and observed to be protective (p < 0.05) in both the C. trachomatis (Figure 4(A) ) and C. muridarum (Figure 4 ceived anti-CD4 antibody on days 6, 5, and 4 prior to challenge followed by additional injection every third day to ensure the depletion lasted for the duration of the infection (3 to 4 weeks). Mice not treated with anti-CD4 antibody maintained normal levels of CD4+ T-cells. Using the schedule of antibody injections described, depletion of CD4+ T-cells was effectively maintained at >95% reduction throughout the course of study (data not shown).
Role of CD4+ T-Cells in the Resolution of Primary Infection Following Vaccine Induced Immunity
In the C. trachomatis model, mice immunized with adjuvant-control and then CD4+ T-cell depleted, exhibited a half-log increase in vaginal bacterial shedding compared to the non-CD4+ T-cell depleted adjuvant-control group ( Figure   6 (A)) on day 7 post-challenge. The CD4+ T-cell depleted group maintained a higher level of bacterial shedding throughout the course of the study with only 10% of the mice resolving Chlamydial urogenital infection by day 25 compared to 30% in the non-CD4+ T-cell depleted group [p = 0.2910] ( Table 1) . On day 7 post-challenge, the live EB-immunized non-CD4+ T-cell depleted group and live EB-immunized CD4+ T-cell depleted group exhibited a 2 and 3-log reduction in shedding, respectively, compared to the corresponding adjuvant-control-immunized group (Figure 6(A) ). Ninety percent of the mice in both the live EB-immunized non-CD4+ T-cell depleted and live EB-immunized CD4+ T-cell depleted groups were able to clear the urogenital infection by day 25 [p = 0.7632] ( Table 1) . On day 7 post-challenge, the nMOMP-immunized non-CD4+ T-cell depleted and nMOMP-immunized CD4+ T-cell depleted groups exhibited a 2 and 1.5-log reduction in shedding, respectively, in relation to their corresponding adjuvant-control group (Figure 6(A) ). The nMOMP-immunized non-CD4+ T-cell depleted group and the nMOMP-immunized CD4+ T-cell depleted group maintained their same levels of urogenital bacterial shedding throughout the course of the study (Figure 6(A) ). Similar to the EB-immunized non-CD4+ T-cell depleted group, 90% of the nMOMP-immunized non-CD4+ T-cell depleted mice resolved the urogenital infection by day 25 (Table 1 ). In contrast, the nMOMP-immunized CD4+ T-cell depleted group maintained higher levels of urogenital Chlamydial shedding throughout the course of the study compared with nMOMP-immunized or live EB-immunized groups without depletion, and the live EB-immunized CD4+ T-cell depleted group ( Figure 6(A) ). Only 50% of the nMOMP-immunized CD4+ T-cell depleted mice resolved the Chlamydial infection by day 25 compared to 90% in the nMOMP-immunized non-CD4+ T-cell depleted group [p = 0.0704] ( Table 1 ).
In the C. muridarum model, C57BL/6 mice immunized with adjuvant and CD4+ T-cell depleted, exhibited a 1-log increase in shedding compared to the non-depleted adjuvant-control group (Figure 6 (B)) on day 7 post-challenge. The CD4+ T-cell depleted group maintained a higher level of shedding throughout the course of study with none of the mice resolving the infection by day 28 compared to 60% in the non-CD4+ T-cell depleted adjuvant-control group [p = 0.0054] ( Table 2) . On day 7 post-challenge, the live EB-immunized non-CD4+ depleted group and the live EB-immunized CD4+ T-cell depleted group exhibited a 3 and 3.5-log reduction in shedding, respectively, in relation to their corresponding adjuvant-control group (Figure 6(B) ). All the live EB-immunized non-CD4+ T-cell depleted mice and 90% of the live EB-immunized CD4+ T-cell depleted mice were able to clear the infection by day 28 [p = 0.5000] ( Table 2) . On day 7 post-challenge, the nMOMP-immunized non-CD4+ T-cell depleted and the nMOMP-immunized CD4+ T-cell depleted groups exhibited a 1 and 3-log reduction in shedding, respectively, in relation to their corresponding adjuvant-control group (Figure 6(B) ). The nMOMP-immunized CD4+ T-cell depleted group maintained higher levels of Chlamydia urogenital shedding throughout the course of the study compared with nMOMP-immunized non-CD4+ T-cell depleted group, live EB-immunized non-CD4+ T-cell depleted group, and EB-immunized CD4+ T-cell depleted group (Figure 6(B) ). Only 40% of the nMOMP-immunized CD4+ T-cell depleted mice resolved the Chlamydial infection by day 28 compared to 60% in the nMOMP-immunized non-CD4+ T-cell depleted group [p = 0.3281] ( T-cells to resolve urogenital infection following intravaginal challenge in either the C. muridarum or the C. trachomatis model. Similar to our findings in mice immunized with live EBs by the intraperitoneal route, Nogueria et al. [41] observed that C57BL/6 mice allowed to clear a primary C. trachomatis serovar L2
infection following intranasal challenge before CD4+ T-cell depletion, were protected against infection following a secondary intravaginal challenge. Protective immunity against genital C. trachomatis infection following the intranasal challenge was not dependent on antibody response but was mediated by both CD4+
and CD8+ T-cells; however, either CD4+ or CD8+ T-cells were sufficient for protection [41] . Both the C. muridarum and C. trachomatis mouse models have value for evaluating human vaccine candidates. Neither model completely mimics Chlamydia infection in women, but each model provides some insight into how a specific vaccine could be protective in humans. The C. muridarum model mimics the acute phases of human infection [23] [42] and can be used to study pathogenesis of Chlamydia upper genital tract infection [11] . In contrast, the C. trachomatis model in many ways parallels the course and outcome of infection observed in most women with an asymptomatic and self-limiting infection with low frequency of severe upper genital tract sequelae [43] . Neither model allows for development of chronic infection observed in humans [23] [44] although the C. trachomatis model does allow for the evaluation of recurrent infections which is a frequent occurrence in humans [16] [24] . In addition, C. muridarum and C. trachomatis strains differ in their responses to IFN-γ. In particular, C. trachomatis strains are more sensitive to IFN-γ mediated inhibition, both in vitro and in vivo, whereas C. muridarum is relatively resistant [45] [46]. This may suggest possible differences in their response to other cytokines [31] [47] [48] . Therefore, the C. trachomatis model could be more clinically relevant when investigating cytokine profiles during the course of infection [48] . However, C. trachomatis infection in mice resolves in the absence of adaptive immunity while C. muridarum infection does not [16] [49] . Therefore, the C. muridarum model may be better for defining protective adaptive immune responses following natural infection or vaccination. When humanized mice are used, such as HLA-DR4 [50] or BLT mice [51] , the C. trachomatis challenge model may be more advantageous in terms of evaluating human vaccine candidates since both the MHC-II antigen and the vaccine candidates are of human origin. Ultimately, both models
